If You Invested in Achilles Therapeutics Plc (ACHL)

Achilles Therapeutics plc (ACHL) is a clinical-stage biopharmaceutical company that has focused on developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors. The company’s work centers on clonal neoantigens, which are protein markers unique to each individual and expressed on the surface of every cancer cell, but absent from healthy tissue. By concentrating on these targets, Achilles has aimed to direct immune responses specifically toward tumor cells.

According to company disclosures, Achilles has used DNA sequencing data from each patient together with its proprietary PELEUS™ bioinformatics platform. PELEUS applies AI-driven, Bayesian statistical algorithms to distinguish clonal from subclonal mutations by integrating sequencing information from multiple tumor regions. This information has provided the foundation for Achilles’ VELOS™ manufacturing process to produce clonal neoantigen-reactive T cells, or cNeT, designed to recognize and attack cancer cells bearing those clonal neoantigens.

Achilles has described itself as a clinical-stage company with Phase I/IIa trials in solid tumors. Its CHIRON trial has involved patients with advanced non-small cell lung cancer (NSCLC), and its THETIS trial has involved patients with recurrent or metastatic melanoma. These trials have been used to evaluate safety, tolerability, cNeT dose levels, engraftment, and clinical activity, including in cohorts with enhanced host conditioning intended to support T cell persistence.

The company’s platform has been closely linked to the TRACERx® study (TRAcking Cancer Evolution through therapy (Rx)), a large tumor evolution program led at University College London (UCL). TRACERx has generated deep sequencing, multi-region and multi–time point genetic data from thousands of tumor samples from lung cancer patients. Achilles has reported exclusive commercial rights to TRACERx data for development of neoantigen-targeting cell therapies and, in some contexts, vaccines. Insights from TRACERx have supported the identification of clonal neoantigens that are present on all tumor cells but absent from healthy tissue.

In its public communications, Achilles has highlighted translational science aimed at understanding the drivers of durable T cell engraftment and immune evasion at the antigen level. The company has reported improvements in its VELOS manufacturing process, including higher cNeT doses delivered in clinical programs, and has emphasized the role of PELEUS in selecting neoantigen targets with high immunogenic potential and low immune evasion risk.

Achilles has also engaged in collaborations and transactions related to its technology and data assets. It announced a research collaboration with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines using Achilles’ AI-driven tumor-targeting technology together with Arcturus’ self-amplifying mRNA platform. In addition, Achilles disclosed a transaction transferring commercial rights to data and samples from the TRACERx NSCLC study and its Material Acquisition Platform (MAP) to AstraZeneca, with AstraZeneca taking over sponsorship of MAP and receiving tumor samples and data collected in that network.

In later updates, Achilles reported that it would discontinue development of its TIL-based cNeT program and close the CHIRON and THETIS Phase I/IIa clinical trials. The company indicated that it would explore further engagement with third parties developing alternative modalities to target clonal neoantigens, such as neoantigen vaccines, antibody-drug conjugates (ADCs), and TCR-T therapies. It also described a process of exploring strategic alternatives, including potential acquisitions, mergers, business combinations, asset sales, licensing, or other transactions.

Subsequently, Achilles announced a voluntary transition of its American Depositary Shares (ADSs) from the Nasdaq Global Market to the Nasdaq Capital Market, in connection with Nasdaq minimum bid price requirements. The company later disclosed that it had notified Nasdaq of its intention to voluntarily delist its ADSs from Nasdaq and to deregister its ADSs under Section 12(b) of the Securities Exchange Act of 1934. Achilles stated that it intended to file a Form 25 (Notification of Removal from Listing) and a Form 15 (Certification and Notice of Termination From Registration), and that it had called a General Meeting to obtain shareholder approval to commence a members’ voluntary liquidation. The company indicated that the planned delisting was being undertaken in connection with the contemplated liquidation.

Following delisting, Achilles has stated that any trading in its ADSs would be limited to privately negotiated sales and potentially over-the-counter markets if a broker were to make a market, with no assurance that such trading would occur. Upon filing of Form 15, the company’s obligation to file periodic reports with the SEC, including Forms 20-F and 6-K, would be suspended and would terminate when deregistration becomes effective.

For investors and observers, Achilles Therapeutics represents a case study in the application of AI-enabled bioinformatics and tumor evolution data to the design of precision T cell therapies targeting clonal neoantigens, as well as the subsequent strategic decisions around clinical programs, collaborations, asset sales, and corporate structure, including a planned voluntary liquidation and delisting from a major U.S. exchange.